Dyadic International, Inc. products

Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic’s naturally derived C1 cells went through random mutagenesis. This development brought about highly beneficial changes and transformed the shape of the C1 cells, from long strands to short, grain-sized sections.

Dyadic’s newly developed Dapibus™ filamentous fungal based microbial protein production platform is reenginnered to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness. The current focus for the Dapibus™ platform is in our Alternative Proteins business segment. Given the Dyadic’s industrial heritage, the expertise to rapidly achieve commercial scale within margin sensitive markets such as food and nutrition enzymes, provides our partners with the ability to move from demonstration to commercial production quickly and efficiently.